Trial Profile
A Phase I Trial With Cohort Expansion of Enzalutamide in Combination With Gemcitabine and Nab-Paclitaxel for the Treatment of Advanced Pancreatic Cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Enzalutamide (Primary) ; Gemcitabine; Paclitaxel
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Adverse reactions
- 05 Dec 2019 Status changed from active, no longer recruiting to completed.
- 03 Jul 2019 Planned End Date changed from 1 Jul 2019 to 1 Dec 2019.
- 10 Jan 2019 Planned End Date changed from 1 Dec 2018 to 1 Jul 2019.